Download Addenbrooke’s Cognitive Examination (ACE-III) PDF

Addenbrooke's Cognitive Examination (ACE-III): Guide & PDF

The Addenbrooke’s Cognitive Examination-III (ACE-III) is the most widely used standardized bedside cognitive screening test designed to detect cognitive impairment, dementia, and mild cognitive impairment (MCI) and other neuro-degenerative conditions. Unlike smaller or brief tools like MMSE, ACE-III is a multidomain cognitive screening instrument especially valued for its greater sensitivity and domain coverage.  The test consists of 19 structured tasks assessing five main cognitive domains like attention, memory, verbal fluency, language, and visuospatial processing.

The aim of ACE-III is to assess five cognitive domains — attention, memory, verbal fluency, language, and visuospatial abilities, with a total score of 100 and takes approximately 15–20 minutes to administer.

• Normal ACE-III score: ≥ 88
• Borderline dementia: ≤ 82
• Possible MCI: 83–87

This article explains ACE-III. How it is designed to provide a broad yet time-efficient evaluation of cognitive functioning. How it is scores, clinical cut-off values, interpretation, and when it should be used, along with its role in neurophysiology and research.

In this article we will understand:

• Comparison with MMSE and Mini-ACE
• ACE-III scoring and cut-off interpretation
• Domain-wise score breakdown
• ACE-III PDF download
• Clinical uses and limitations

Addenbrooke’s Cognitive Examination (ACE-III):  Overview

What Is the Addenbrooke’s Cognitive Examination?

The Addenbrooke’s Cognitive Examination assesses several core cognitive functions in a single structured assessment and is a multidomain cognitive screening battery.

To improve early detection of dementia and differentiate between dementia subtypes, it was originally developed at Addenbrooke’s Hospital, Cambridge, particularly for:

• Vascular dementia
• Alzheimer’s disease
• Parkinson’s disease dementia
• Frontotemporal dementia

ACE evaluates both global cognition and individual cognitive domains, unlike brief screening tools, making it suitable for subtle and early-stage cognitive changes.

ACE-III Score Interpretation - Quick Guide: 

Versions of the Addenbrooke’s Cognitive Examination

There are several versions of ACE and each of them are refined for better usability and accuracy. ACE-III is currently the most widely used and recommended version in clinical practice.

How Is the Addenbrooke’s Cognitive Examination Administered?

ACE requires very minimal equipment and can be administered in clinics, hospitals, memory clinics and research studies.

ACE Scoring and Cut-Off Values:

Most commonly used ACE-III cut-off scores as follows:

Cut-off scores may also vary depending on education level, age, language version and cultural norms. For accurate interpretation, normative adjustments are recommended.

Is Addenbrooke’s Cognitive Examination Better Than MMSE?

The ACE was more specifically developed to overcome the limitations of the MMSE. ACE is particularly superior in detecting - Early Alzheimer’s disease, frontotemporal dementia and language-led cognitive syndromes.

Clinical Uses of the Addenbrooke’s Cognitive Examination

1. Dementia Screening: As a first-line cognitive screening tool in memory clinics ACE is widely used.

2. Differential Diagnosis - The distinct domain patterns help differentiate among :

• Memory-dominant - Alzheimer’s disease

• Language and fluency deficits - Frontotemporal dementia 

• Attention and executive dysfunction - Vascular dementia

3. Mild Cognitive Impairment (MCI)

Making it useful for identifying MCI before functional impairment becomes severe, ACE is sensitive to subtle cognitive decline.

4. Monitoring Disease Progression

Repeated ACE assessments allow clinicians to:

• Track cognitive decline
• Monitor progression over time
• Evaluate treatment response

Validity and Reliability of ACE

Across populations and languages, ACE has been extensively validated.

Psychometric Strengths

• Criterion validity and excellent construct.
• For dementia, high sensitivity and specificity.
• In multiple languages, validated translations.
• Test–retest reliability and strong inter-rate.

Better diagnostic accuracy by ACE-III than many brief cognitive screens.

What is “ACE 111”?

The term "ACE 111" is a quick search term or a shortcut used by students referring to ACE-III (total score 100) or ACE-R variants. It has created confusion and there is official ACE test with a maximum score of 111 in current clinical practice.

Addenbrooke’s Cognitive Examination in Research

ACE is widely used in:

• Neurodegenerative disease research
• Cognitive aging research
• Epidemiological studies
• Clinical trials

Allows researchers to correlate specific cognitive deficits with, due to its Its domain-level scoring :

• EEG and functional connectivity patterns
• Neuroimaging findings
• Disease progression markers
• Biomarkers

Limitations of the Addenbrooke’s Cognitive Examination

Despite its strengths, ACE has some limitations, d, the limitations are:

• It is less sensitive to very mild executive dysfunction
• The performance on ACE test is influenced by literacy and education.
• For full neuropsychological assessment, it is not a replacement.
• For accuracy, requires trained administration.

ACE should not be used as a standalone diagnostic test but as a screening tool.

Cultural / Educational Considerations: ACE 

Performance of ACE can be affected by low literacy, limited formal education and language barriers. To address these shortcomings:

• Interpret results alongside clinical history
• Use validated local-language versions
• Apply education-adjusted cut-offs

Mini-ACE Features:

For rapid screening, the Mini-ACE is a shortened version designed. ACE-III remains preferred for detailed assessment and Mini-ACE is useful only in busy clinical settings.

Cognitive Domains Assessed in ACE-III

Attention

Through tasks that require orientation, immediate attention, and working mental manipulation, attention is assessed. These taks include:

• Answering the current date, season, and location type of questions.
• A repetition of three simple words.
• Serial subtraction, for example, subtracting seven repeatedly from 100.

These parameters are frequently impaired in dementia and delirium and by evaluating the parameters gives an idea about alertness, sustained attention, and mental control.

Memory

The core domains of memory evaluated are short-term, episodic, and semantic memory and it includes:

• Recall of well-known historical facts or past events.
• A delayed recall of the three previously repeated words.
• Recall and learning of a fictional name and address.

Allowing assessment of encoding, retention, and retrieval, rather than isolated recall, the memory component is distributed across five sections throughout the test.

Verbal Fluency

The verbal fluency is tested using:

• Generating as many words as possible beginning with a specified letter in one minute - Letter fluency
  
• Naming as many animals as possible in one minute - Category fluency

These tasks are particularly sensitive to frontotemporal and subcortical dysfunction and they assess lexical retrieval, executive control, and semantic memory.

Language

Reflecting its importance in daily functioning and dementia differentiation, language is the largest and most detailed domain in ACE-III and it includes:

• For example, placing paper relative to a pencil, is execution of sequenced commands using objects.
• Answering contextual questions and naming objects from line drawings.
  Writing two complete sentences which are grammatically sound. 
• Reading aloud the commonly mispronounced words.
  Repetition of short proverbs and polysyllabic words.

The above mentioned language tasks help us assess comprehension, expression, naming, repetition, reading, and semantic processing.

Visuospatial Processing

The visuospatial abilities are assessed through tasks that require:

• Drawing a clock face with hands set to a specified time
• Copying geometric figures
• Identifying partially obscured letters
• Counting arrays of dots.
  

This domain evaluates parameters which are often impaired in Alzheimer’s disease, vascular dementia, and Lewy body dementia like visual perception, spatial organization, constructional praxis, and visual attention.

ACE-III Scoring System:

With domain-specific weightings, ACE-III yields a total score out of 100:

Interpretation of Scores: 

• ≥ 88 means normal cognition
  
• 83–87 shows borderline results or  inconclusive
  
• ≤ 82 implies abnormal, suggestive of cognitive impairment

The above scores and their levels must always be interpreted in the context of clinical history, education, language, and neurological examination.

Validity and Diagnostic Accuracy:

 ACE-III’s initial validation studies demonstrated that:

• Highly correlated with ACE-R - r = 0.99
• Quick to administer- Approximately 15 minutes
• Highly sensitive and specific - For  dementia detection

ACE-III , at the cut-off score of 88, shows:

• Specificity up to 0.96
• Sensitivity up to 1.00

At the cut-off score of 82:

• Specificity of 1.00
• Sensitivity approximately 0.93

ACE-III has been shown to:

• Helps differentiate dementia from subjective memory complaints individuals.
• Distinguish between early-onset dementia and healthy controls.
• Correlate well with standard neuropsychological assessments

Clinical Recommendations and Limitations

A 2019 Cochrane meta-analysis concluded that:

• ACE-III is a valid and reliable cognitive screening tool and it should not be used in isolation.
  
  
• It is not a standalone diagnostic instrument must serve as an adjunct to comprehensive clinical assessment.
  

Especially in early or atypical presentations, ACE-III does not replace full neuropsychological testing.

Translations and Localized Versions

The ACE-III test batteries have been localized for clinical use in United Kingdom, United States, India, Australia and New Zealand and translated into 19 languages. Improving diagnostic accuracy across populations, localized versions account for linguistic, cultural, and educational differences.

Key Features of Mini-ACE

The Mini-ACE (M-ACE) is a shortened version developed for rapid cognitive screening.

• Across settings a score ≤ 21 is strongly indicative of dementia.
• As compared to MMSE, M-ACE demonstrates superior diagnostic utility.
• Mini-ACE should be used only as part of a full clinical evaluation, like ACE-III.

Addenbrooke’s Cognitive Examination and EEG / Neurophysiology

The ACE domain scores are increasingly correlated with - EEG slowing, functional connectivity changes, microstate alterations and network-level dysfunction.

Especially in dementia and epilepsy-related cognitive impairment, this makes ACE particularly valuable in cognitive–neurophysiology research.

Frequently Asked Questions 

1. Is Addenbrooke’s Cognitive Examination better than MMSE?

Yes, especially for early dementia, ACE provides broader domain coverage and higher sensitivity.

2. How long does ACE take to administer?

It takes approximately 15–20 minutes.

3. What is the normal ACE-III score?

Though cut-offs vary by population it is typically ≥ 88.

4. Can ACE diagnose dementia?

No, when combined with clinical evaluation, ACE is a screening tool that supports diagnosis.

1. Neurotypical Meaning: What It Really Means in Neuroscience 
2. Sluggish Cognitive Tempo (SCT): Understanding Cognitive Disengagement Syndrome (CDS)
3. Cognitive Empathy: Neural Mechanisms, Functional Roles, and Development
4. Brain on Fire Condition: Anti-NMDA Receptor Encephalitis 
5. Jean Piaget’s Theory of Cognitive Development
6. PI Cognitive Assessment: Meaning, Scoring and Examples
7. Cognitive Ergonomics: Prinicples, Applications, and Why It Matters